Equine CXCL3 (C-X-C motif chemokine ligand 3), also known as GRO-γ (growth-regulated oncogene gamma), is a proinflammatory chemokine belonging to the CXC chemokine family, which also includes CXCL1 (GRO-α) and CXCL2 (GRO-β) that regulate neutrophil recruitment during inflammatory responses. In horses (Equus caballus), CXCL3 is produced by macrophages, epithelial cells, endothelial cells, and fibroblasts in response to proinflammatory cytokines such as IL-1β and TNF-α, microbial infection, or tissue injury. CXCL3 primarily signals through the chemokine receptor CXCR2, which is expressed on neutrophils and other innate immune cells, promoting chemotaxis, activation, and migration of neutrophils to sites of infection or inflammation. In equine health, CXCL3 contributes to innate immune responses against bacterial and viral pathogens, particularly in tissues such as the respiratory tract and skin, where rapid neutrophil recruitment is important for controlling infection. CXCL3-mediated neutrophil trafficking is also relevant in equine inflammatory conditions, including respiratory diseases such as equine influenza and inflammatory airway disease, where chemokine-driven neutrophil accumulation influences airway inflammation and immune defense. Consequently, equine CXCL3 is studied in veterinary immunology and respiratory disease research to better understand neutrophil-mediated inflammation and host–pathogen interactions in horses.